Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.

DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient ...

On Time Girl took the Forward Gal Stakes (G3) at Gulfstream Park and then two races later Nearly captured the Holy Bull Stakes (G3). Nearly—who if all goes to plan will aim to make his only other ...

Amplitude, Inc. , the leading AI analytics platform, today announced that it will release its financial results for the fourth quarter and full year of 2025 after market close on Wednesday, February ...

Three undergraduates, one medical student and one doctoral student were named among this year’s classes of Marshall, ...

Bolt d'Oro has Bold Reason through Sadler's Wells in his sire line, but the Hail to Reason/Djeddah cross is more notably ...

Curious about what's happening in wellness right now? Here's your 2026 wellness download, straight from the experts.

While MP board class 11 exams are nearing, having a clear understanding of syllabus and marking scheme is essential and ...

The structural and functional characteristics of mitochondria shape their role as signaling organelles, with far-reaching ...

Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...

From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC ...